Zimmer Biomet Holdings, Inc. (ZBH) Set to Announce Earnings on Monday
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is scheduled to be posting its quarterly earnings results on Monday, October 30th. Analysts expect Zimmer Biomet Holdings to post earnings of $1.83 per share for the quarter. Zimmer Biomet Holdings has set its Q3 guidance at $1.72-1.77 EPS and its FY17 guidance at $8.20-8.30 EPS.
Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $2.10 by ($0.02). Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The business had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. During the same period last year, the firm posted $2.02 earnings per share. Zimmer Biomet Holdings’s quarterly revenue was up 1.1% compared to the same quarter last year. On average, analysts expect Zimmer Biomet Holdings to post $8.24 EPS for the current fiscal year and $8.81 EPS for the next fiscal year.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at 122.35 on Monday. The firm has a 50-day moving average price of $117.08 and a 200 day moving average price of $120.37. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.49. The firm has a market capitalization of $24.74 billion, a price-to-earnings ratio of 34.85 and a beta of 1.19.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be given a $0.24 dividend. The ex-dividend date is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.78%. Zimmer Biomet Holdings’s dividend payout ratio is currently 27.59%.
A number of equities research analysts have recently weighed in on ZBH shares. Bank of America Corporation reiterated a “buy” rating and issued a $158.00 price objective on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. BidaskClub lowered Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Piper Jaffray Companies restated a “buy” rating and set a $135.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday, July 28th. Zacks Investment Research lowered Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, Canaccord Genuity lowered Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and dropped their price target for the company from $141.00 to $135.00 in a research report on Friday, July 28th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Zimmer Biomet Holdings currently has an average rating of “Hold” and an average target price of $136.55.
In other Zimmer Biomet Holdings news, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $121.74, for a total transaction of $2,067,875.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.07% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Zimmer Biomet Holdings, Inc. (ZBH) Set to Announce Earnings on Monday” was published by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/23/zimmer-biomet-holdings-inc-zbh-set-to-announce-earnings-on-monday.html.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.